

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows, without prejudice or disclaimer. This listing of the claims replaces all prior listings.

1-5. Canceled

6. (Currently amended) The expression vector of claim 11 further comprising at least one additional tumor-associated antigen.

7-8. Canceled

9. (Previously Amended) The expression vector of claim 6 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

10. (Previously Amended) The expression vector of claim 9 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

11. (Currently amended) ~~The expression vector of claim 1 further comprising A poxvirus expression vector for expressing the BFA4 protein in a cell, the vector comprising the nucleic acid sequence of SEQ ID NO.: 1 and~~ at least one nucleic sequence encoding an angiogenesis-associated antigen, ~~wherein administration of the vector to a mammal induces a T-cell response against the BFA4 protein.~~

12-13. Canceled

14. (Previously presented) The expression vector of claim 11 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

15. (Previously presented) The expression vector of claim 14 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

16-20. Canceled

21. (Currently amended) The expression vector of claim 1, 6, 11 and 16 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.

22-23. Previously Canceled

24. (Previously Amended) The expression vector of claim 21 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

25. (Previously Amended) The poxvirus of claim 24 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

26. (Currently amended) A composition comprising a poxvirus expression vector of claim 11 and a pharmaceutically acceptable carrier.

27-28. Canceled

29. (Currently amended) The ~~expression vector composition~~ of claim 26 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

30. (Currently amended) The ~~poxvirus composition~~ of claim 29 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

31-39. Canceled

40. (Previously Presented) The expression vector of claim 6 wherein the at least one additional tumor-associated antigen has the amino acid sequence of SEQ ID NO:4.

41-48. Cancelled

49. (Currently amended) The expression vector of claim 44 ~~54~~ further comprising a nucleic acid encoding at least one additional tumor-associated antigen.

50-51. Cancelled

52. (Previously Amended) The expression vector of claim 49 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

53. (Previously Amended) The expression vector of claim 52 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

54. (Currently amended) A poxvirus ~~The expression vector of claim 44 further comprising a nucleic acid sequence encoding a BFA4 protein having the amino acid sequence of SEQ ID NO:2 and at least one nucleic acid sequence encoding an angiogenesis-associated antigen, wherein administration of the vector to a mammal induces a T-cell response against the BFA4 protein.~~

55-56. Cancelled

57. (Previously Amended) The expression vector of claim 54 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

58. (Previously Amended) The expression vector of claim 57 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

59. (Currently amended) The expression vector ~~selected from the group consisting of the expression vector of claims 44, 49 and 54~~ further comprising at least one nucleic acid sequence encoding a co-stimulatory component.

60-61. Cancelled

62. (Previously Amended) The expression vector of claim 59 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

63. (Previously Amended) The poxvirus of claim 62 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

64. Cancelled

65. (Previously amended) A composition comprising an expression vector of claim 49 and a pharmaceutically acceptable carrier.

66. (Previously amended) A composition comprising an expression vector of claim 54 and a pharmaceutically acceptable carrier.

67-69. Cancelled

70. (New) A composition comprising a poxvirus expression vector of claim 6 and a pharmaceutically acceptable carrier.

71. (New) The composition of claim 70 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

72. (New) The composition of claim 71 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

73. (New) The expression vector of claim 6 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.

74. (New) The expression vector of claim 21, 59, or 73 wherein the co-stimulatory component is B7.1.

75. (New) The expression vector of claim 21, 59, or 73 wherein the co-stimulatory component is TRICOM comprising B7.1, LFA-3 and ICAM-1.

76. (New) The expression vector of claim 11 or 54 wherein the angiogenesis-associated antigen is selected from the group consisting of vascular endothelial growth factor, vascular endothelial growth factor receptor EPH receptors, epidermal growth factor receptor, basic fibroblast growth factor, platelet-derived cell growth factor, platelet-derived endothelial cell growth factor, a transforming growth factor, endoglin, an Id proteins, uPA, uPAR, a matrix metalloproteinases, thrombospondin, and surface proteoglycan NG2.

77. (New) The expression vector claim 6 or 49 wherein the at least one additional tumor-associated antigen is selected from the group consisting of gp100, TRP-1, NY-ESO-1, a MAGE antigen, MAGE-1, MAGE-3, carcinoembryonic antigen, MUC-1, and NY-BR-1.